AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Hemophilia

Recent research efforts aimed at curing Hemophilia.

Last updated
Also available in
Français — Hémophilie

Hemophilia

Overview

Hemophilia is usually an inherited bleeding disorder in which blood does not clot normally because factor VIII is low or absent in hemophilia A, or factor IX is low or absent in hemophilia B. Its severity depends largely on the remaining factor level: severe disease can cause spontaneous bleeding, especially into joints and muscles, while bleeding in the head or other vital organs can be life-threatening. It is X-linked and therefore more often causes serious symptoms in males, but females can also have hemophilia or clinically important bleeding symptoms. CDC overview CDC inheritance information

With modern specialist care, many people with hemophilia can live long, healthy lives, but repeated bleeding can still cause chronic joint damage, pain, disability, and potentially fatal complications. The standard of care is individualized preventive treatment (“prophylaxis”) with replacement factor VIII or IX, or selected non-factor medicines that reduce bleeding risk; prompt treatment of breakthrough bleeds, inhibitor testing, physical therapy, and comprehensive hemophilia-treatment-center care remain important. CDC hemophilia treatment centers WFH management guideline

Scope of Recent Research (2020–present)

Research since 2020 has been highly active, led by liver-directed gene-transfer studies that aim to make the body produce its own clotting factor after a single infusion. The central questions are no longer only whether this approach can reduce bleeding, but how durable, safe, broadly eligible, repeatable, and affordable it will be; meanwhile, gene editing and stem-cell approaches seek a more permanent correction of the underlying genetic defect. Two U.S.-approved gene therapies now provide important proof of principle, but the available evidence does not yet establish a universal, lifelong cure for hemophilia. FDA Roctavian approval FDA Hemgenix information CRISPR and gene editing review

Major Breakthroughs and Emerging Therapies

The most consequential advance has been adeno-associated virus (AAV) gene transfer to the liver. AAV is a modified virus used as a delivery vehicle: it carries a working DNA sequence for factor VIII or factor IX into liver cells, which then produce the missing clotting factor. In June 2023, the U.S. Food and Drug Administration approved valoctocogene roxaparvovec-rvox (Roctavian) for eligible adults with severe hemophilia A, making it the first approved gene therapy for that condition in the United States. FDA Roctavian approval In the phase 3 GENEr8-1 study, treated bleeding fell by 84.5% at two years, but factor VIII production declined over time, illustrating why it should be described as a potentially durable functional treatment rather than a confirmed permanent cure. GENEr8-1 two-year results

For hemophilia B, etranacogene dezaparvovec-drlb (Hemgenix) uses an AAV5 vector carrying the high-activity Padua version of factor IX. FDA approved it in November 2022 for defined adults with hemophilia B. FDA Hemgenix information Five-year phase 3 follow-up reported stable mean factor IX activity of 36.1 IU per deciliter, a 63% reduction in bleeding versus the pre-treatment lead-in period, and a 96% reduction in factor IX use. These results are among the strongest evidence so far that a one-time treatment can provide multiyear disease control in hemophilia B. HOPE-B five-year analysis

A second hemophilia B program, fidanacogene elaparvovec, showed that several AAV platforms can achieve clinically meaningful factor IX expression. In the phase 3 BENEGENE-2 study, bleeding decreased 71% compared with the prophylaxis lead-in period, and mean factor IX activity was 26.9% at 15 months. However, 62% of participants received glucocorticoids because of elevated liver enzymes, falling factor IX levels, or both—an important reminder that immune-mediated liver inflammation remains a central limitation of current AAV gene therapy. BENEGENE-2 phase 3 results

Gene editing is a more explicitly curative strategy because it aims to repair a disease-causing sequence or permanently insert a functional factor gene at a selected genomic site. CRISPR-based editing, base editing, prime editing, and targeted gene insertion have restored factor production in patient-derived cells and hemophilia animal models, but they remain preclinical for hemophilia. For example, a 2024 study corrected common hemophilia A mutations and restored factor VIII expression in laboratory and patient-cell models using DNA base editors. Base editing for hemophilia A The major hurdles are delivery to enough target cells, unintended “off-target” DNA changes, immune responses, and proving long-term safety before first-in-human trials. Targeted gene insertion review CRISPR and gene editing review

Cell-based strategies remain earlier-stage alternatives. One approach modifies a patient’s own blood-forming stem cells outside the body with a lentiviral vector carrying factor VIII, then returns the edited cells after transplantation; unlike AAV DNA, lentiviral DNA can integrate into the genome, potentially allowing persistent expression but adding conditioning and insertional-safety concerns. A recruiting phase 1 study in China is testing autologous lentiviral factor VIII gene-modified stem cells in people with hemophilia A. Lentiviral FVIII gene therapy trial A separate proposed U.S. phase 1 program, ET3-201, would evaluate autologous CD34-positive stem cells modified with a factor VIII lentiviral vector. ET3-201 stem-cell gene-therapy trial

Clinical Trials and Experimental Approaches

The pivotal clinical evidence comes from phase 3 AAV gene-transfer trials in adults. BioMarin’s GENEr8-1 study of Roctavian enrolled 134 men with severe hemophilia A; at week 104, annualized treated bleeds had decreased by 84.5%, though factor VIII expression showed a declining trajectory. GENEr8-1 two-year results CSL Behring’s HOPE-B study of Hemgenix enrolled 54 men with severe or moderately severe hemophilia B and has now reported five years of follow-up, with sustained factor IX activity and lower bleeding. HOPE-B five-year analysis Pfizer’s phase 3 BENEGENE-2 study of fidanacogene elaparvovec also met superiority criteria over prior factor IX prophylaxis, although many screened participants were excluded because of pre-existing antibodies against the AAV capsid. BENEGENE-2 phase 3 results

Current studies increasingly emphasize long-term surveillance rather than only initial bleeding reduction. Pfizer’s phase 3, non-interventional long-term follow-up study is monitoring prior recipients of giroctocogene fitelparvovec for hemophilia A and fidanacogene elaparvovec for hemophilia B through an estimated 2040 completion date, including assessment of AAV-vector integration in liver tissue when samples become clinically available. Pfizer long-term follow-up study St. Jude Children’s Research Hospital is also planning an observational liver-biopsy study of adults previously treated with AAV factor VIII or IX gene transfer to investigate long-term liver effects. St. Jude liver-biopsy study

Methodologies and Scientific Approaches

Most clinical programs use a single intravenous infusion of a liver-tropic AAV vector. Investigators measure factor VIII or IX activity, annualized bleeding rate, use of replacement factor, liver enzymes such as alanine aminotransferase, immune responses to the AAV capsid, and development of clotting-factor inhibitors. These biomarkers connect the biological effect—new factor production—to outcomes that matter to patients, including fewer bleeds and less need for prophylactic infusions. GENEr8-1 two-year results HOPE-B five-year analysis

Preclinical editing research uses engineered cell lines, blood outgrowth endothelial cells, patient-derived induced pluripotent stem cells, and mouse models of hemophilia A or B to test correction of factor production and clotting function. Researchers compare delivery systems—including AAV, lentiviral vectors, lipid nanoparticles, and nonviral editing components—and conduct genomic analyses for off-target edits, on-target insertion structure, and long-term expression. Base editing for hemophilia A Targeted gene insertion review

Leading Institutions and Funding

Key industry developers include BioMarin, which developed Roctavian; CSL Behring, which markets Hemgenix; and Pfizer, which sponsored the BENEGENE-2 fidanacogene elaparvovec trial and long-term follow-up programs. FDA Roctavian approval FDA Hemgenix information BENEGENE-2 phase 3 results Academic and clinical contributors include St. Jude Children’s Research Hospital, major hemophilia treatment centers, and international trial networks that provide long-term safety and outcome monitoring. St. Jude liver-biopsy study CDC hemophilia treatment centers

Public and nonprofit infrastructure is also essential. In the United States, CDC funds the Community Counts surveillance program through a cooperative agreement with the American Thrombosis and Hemostasis Network and the U.S. Hemophilia Treatment Center Network; the program tracks bleeding, inhibitors, treatment patterns, and other outcomes relevant to evaluating new therapies in real-world care. CDC Community Counts The World Federation of Hemophilia supports evidence-based international care guidance through its living guideline program, while the National Heart, Lung, and Blood Institute supports clinical, translational, and implementation research in bleeding disorders. WFH management guideline CDC surveillance-program evaluation

Strengths, Limitations, and Challenges

The major strength of gene therapy is that one infusion can produce endogenous factor at levels sufficient to markedly reduce bleeding and dependence on frequent prophylaxis. Hemophilia B results, especially the five-year Hemgenix data, provide encouraging evidence of sustained expression. HOPE-B five-year analysis Yet AAV gene transfer is not currently suitable for everyone: neutralizing antibodies may exclude patients or reduce effectiveness, most trials have enrolled adults without active inhibitors or major liver disease, and redosing with the same AAV platform is difficult because treatment can trigger anti-AAV immunity. FDA Roctavian approval BENEGENE-2 phase 3 results

Durability is the defining unanswered question, particularly in hemophilia A, where factor VIII output has declined in follow-up studies. Safety monitoring must address liver inflammation, the need for steroids or other immunosuppression, thrombosis if factor levels become excessive, theoretical cancer risk associated with vector DNA, and unknown consequences decades after dosing. GENEr8-1 two-year results FDA Roctavian approval Access is another major challenge: complex eligibility testing, specialized-center capacity, very high upfront costs, and unequal global availability could limit the impact of therapies that otherwise reduce lifelong treatment burden. WFH management guideline

Outlook and Future Directions

As of October 17, 2026, hemophilia is closer than ever to a functional cure for some eligible adults, particularly through long-lasting liver-directed factor IX expression, but it is not yet cured broadly or permanently across the hemophilia population. The most important milestones to watch are longer-term outcomes beyond five to 10 years; evidence in children, women, people with inhibitors, and those with liver disease or pre-existing AAV antibodies; safer immune-management and redosing strategies; and the first carefully monitored human trials of precise gene editing or stem-cell gene therapy. HOPE-B five-year analysis CRISPR and gene editing review Lentiviral FVIII gene therapy trial

References

Don't see your disease? Request a report